Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?

Choosing between a high-growth specialist and a cash-rich mRNA pioneer requires weighing current momentum against long-term potential. Both Axsome Therapeutics (NASDAQ:AXSM) and BioNTech (NASDAQ:BNTX) offer distinct paths for investors.

Axsome is rapidly scaling a portfolio focused on central nervous system disorders, aiming for market leadership in depression and sleep medicine. BioNTech, famous for its COVID-19 vaccine, is now reinvesting its capital into a vast pipeline of cancer immunotherapies. Investors must decide which risk-reward profile better suits their goals.

The case for Axsome Therapeutics

Axsome Therapeutics operates within the competitive landscape of biotech stocks, focusing on therapies for central nervous system conditions. Its current portfolio includes treatments for depression, Alzheimer's disease agitation, migraine, and narcolepsy. The company commercializes products like AUVELITY and SUNOSI using its own internal sales and marketing infrastructure in the United States. It also utilizes licensing agreements, such as its partnership with Pharmanovia for marketing SUNOSI in Europe and the Middle East. Axsome relies on third-party contract research organizations and manufacturers for clinical trials and production.

In its latest annual report, covering FY 2025, revenue reached nearly $638.5 million, representing a significant increase of approximately 65.5% compared to the prior year. Despite this growth, the company recorded a net loss of roughly $183.2 million. The company reported a net margin of negative 28.7% for the year. This loss is largely attributed to the high costs of commercializing new treatments and funding late-stage clinical trials as the company expands its market reach.

As of its December 2025 balance sheet, the debt-to-equity ratio is around 1.4x. This ratio measures a company's total debt relative to the equity held by shareholders. The current ratio, which indicates if a company has enough short-term assets to cover its obligations due within one year, is roughly 1.6x. Free cash flow, which is the cash left over after a company pays for its operating activities and capital equipment, was negative $93.9 million for the year.

The case for BioNTech

BioNTech is a global biopharmaceutical company that gained international recognition for its mRNA-based infectious disease vaccines. The company is currently developing a wide range of investigational therapies, including mRNA cancer immunotherapies and targeted treatments for various cancers. While it serves patients worldwide, the firm is actively building its commercial capabilities in the United States and other major markets. BioNTech does not disclose specific major customer concentrations in its latest filings. It continues to focus on shifting its pipeline toward oncology to diversify its long-term revenue streams.

In its latest annual report, covering FY 2025, revenue reached approximately $3.2 billion, which was a growth of roughly 4.3% compared to the prior year. The company reported a net loss of nearly $1.3 billion for the same period. The company reported a net margin of negative 39.6% for the year. This financial performance follows a period of transition as the company moves beyond its initial pandemic-related growth and invests heavily in research and development for its oncology pipeline.

As of its December 2025 balance sheet, the company has a debt-to-equity ratio of 0.0x. This indicates that BioNTech carries virtually no debt relative to its shareholder equity. The current ratio is approximately 7.5x, suggesting an exceptionally strong ability to cover short-term liabilities with current assets. Free cash flow for FY 2025 was nearly $303.0 million, demonstrating the company's ability to generate cash while funding its extensive research projects.

Risk profile comparison

Axsome Therapeutics faces significant ongoing operating losses and may need additional capital to fund its drug development. The company is substantially dependent on the commercial success of a few approved products and faces high competition from major players like AbbVie (NYSE:ABBV). Furthermore, it deals with complex regulatory approval processes and ongoing patent litigation regarding its core therapies. There are also potential conflicts of interest regarding intellectual property licensed from an entity owned by its Chief Executive Officer.

BioNTech faces the challenge of transitioning away from its pandemic-era revenue sources as global vaccine demand fluctuates. The company relies heavily on its pipeline candidates successfully navigating clinical trials, which is a high-risk endeavor for any firm in the oncology space. Additionally, it faces intense competition from established giants like Pfizer (NYSE:PFE) and AstraZeneca (NYSE:AZN) that are also developing advanced therapies. Market success for its new treatments remains uncertain until regulatory approvals are secured.

Valuation comparison

BioNTech offers a much stronger balance sheet with no debt and significantly higher liquidity, while Axsome operates with more debt and a lower current ratio.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy for 2027?

I'd go with Axsome Therapeutics. What I like is that its Auvelity depression drug is winning prescriptions much faster than the overall market, which is a good sign the business is catching on.

In its Q3 2026 results reported on Nov. 2, Axsome's revenue jumped 52% year over year, led by Auvelity, which added a new use for agitation in Alzheimer's patients in June. The company is still losing money while spending heavily on sales and research, but the good news is that its losses have shrunk significantly as revenue has climbed.

To give BioNTech its due, it has a huge cash pile and posted a profit in Q3 2026. But its revenue is shrinking as COVID vaccine sales fade, and its future depends on cancer treatments that are still being tested.

For anyone building a portfolio with a long time horizon, Axsome is growing fast and has more room to run. Management says several trial results and regulatory decisions are due in the coming quarters, which could widen its reach. The company's fast growth and shrinking losses make it my pick.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, AstraZeneca Plc, Axsome Therapeutics, BioNTech Se, and Pfizer. The Motley Fool has a disclosure policy.